| 7.36 -0.05 (-0.67%) | 03-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 10.52  |
1-year : | 11.85 |
| Resists | First : | 9 |
Second : | 10.14 |
| Pivot price | 8.28 |
|||
| Supports | First : | 7.15 |
Second : | 5.95 |
| MAs | MA(5) : | 7.74 |
MA(20) : | 8.65 |
| MA(100) : | 4.2  |
MA(250) : | 2.72 |
|
| MACD | MACD : | 0 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 14.1 |
D(3) : | 20.2 |
| RSI | RSI(14): 41.2 |
|||
| 52-week | High : | 12.09 | Low : | 0.87 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ANL ] has closed above bottom band by 7.4%. Bollinger Bands are 12.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.8 - 7.86 | 7.86 - 7.9 |
| Low: | 7.07 - 7.11 | 7.11 - 7.15 |
| Close: | 7.29 - 7.37 | 7.37 - 7.43 |
Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trials to induce and stabilize PD-L1 dimerization and disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.
Thu, 19 Mar 2026
Adlai Nortye Ltd. Sponsored ADR (ANL) Raised to Buy: The Reason Behind This Change - Bitget
Thu, 19 Mar 2026
Adlai Nortye Ltd. Sponsored ADR (ANL) Upgraded to Buy: Here's Why - Yahoo Finance
Fri, 13 Mar 2026
ETFs Investing in Adlai Nortye Ltd. Sponsored ADR Stocks - TradingView
Tue, 10 Mar 2026
Adlai Nortye (NASDAQ: ANL) files $600M shelf; 21.5M ADSs resale - Stock Titan
Mon, 09 Mar 2026
Is Adlai Nortye Ltd. Sponsored ADR (ANL) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Wed, 11 Feb 2026
Is the Market Bullish or Bearish on Adlai Nortye Ltd? - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 31 (M) |
| Shares Float | 57 (M) |
| Held by Insiders | 5 (%) |
| Held by Institutions | 6.1 (%) |
| Shares Short | 862 (K) |
| Shares Short P.Month | 136 (K) |
| EPS | -1.14 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.21 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -29.9 % |
| Return on Equity (ttm) | -139 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.35 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -39 (M) |
| Levered Free Cash Flow | -38 (M) |
| PE Ratio | -6.46 |
| PEG Ratio | 0 |
| Price to Book value | 33.45 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.97 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|